Literature DB >> 1846232

Human hepatocellular carcinoma sensitivity to antitumor drugs assayed using the succinate dehydrogenase inhibition test.

T Kanematsu1, Y Maehara, T Matsumata, K Shirabe, K Akazawa, K Sugimachi.   

Abstract

Chemosensitivity of hepatocellular carcinoma tissues from 72 patients to 6 antitumor agents was assayed using the succinate dehydrogenase inhibition test. Sensitivity was positive in 47.2% of tissues exposed to adriamycin, 53.5% to mitomycin C, 10.3% to 5-fluorouracil, 51.5% to cisplatin and aclacinomycin A. respectively, and 52.9% to carboquone. Eight percent of the tissues were sensitive to all 6 drugs, while the resistance rate to all drugs was 36.5%. The remaining 55.5% were sensitive to only some of the drugs. When a comparison of the sensitivity to the 6 drugs was made between two different areas of tumors in 16 patients, positive or negative sensitivity was in a range of 76.9-92.9%. The hypovascular masses seen on the angiography and the histologically well differentiated tumors were resistant to adriamycin, a drug most commonly prescribed to treat patients with liver cancer. For some of these tumors, mitomycin C or carboquone may be effective. Our observation shows that the succinate dehydrogenase inhibition test is useful for determining which drugs will be effective for a particular tumor.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1846232     DOI: 10.1159/000226891

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  2 in total

1.  [Experimental research about effectiveness of transarterial chemoembolization (TACE) in an animal model of hepatocellular carcinoma].

Authors:  J Qian; G Feng; L Trübenbach; P L Pereira; P E Huppert; C D Claussen
Journal:  J Tongji Med Univ       Date:  2001

Review 2.  Mito-Nuclear Communication in Hepatocellular Carcinoma Metabolic Rewiring.

Authors:  Tommaso Mello; Irene Simeone; Andrea Galli
Journal:  Cells       Date:  2019-05-05       Impact factor: 6.600

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.